Switch theme
Sign up to access all valuation multiples
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
1991
580
LTM Revenue $518M
LTM EBITDA $38.1M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioCryst Pharma has a last 12-month revenue (LTM) of $518M and a last 12-month EBITDA of $38.1M.
In the most recent fiscal year, BioCryst Pharma achieved revenue of $451M and an EBITDA of $12.8M.
BioCryst Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioCryst Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $518M | XXX | $451M | XXX | XXX | XXX |
| Gross Profit | $504M | XXX | $438M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | $38.1M | XXX | $12.8M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 3% | XXX | XXX | XXX |
| EBIT | $44.3M | XXX | -$2.5M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | -1% | XXX | XXX | XXX |
| Net Profit | -$46.4M | XXX | -$88.9M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $691M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BioCryst Pharma's stock price is $11.
BioCryst Pharma has current market cap of $2.2B, and EV of $2.7B.
See BioCryst Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.2B | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BioCryst Pharma has market cap of $2.2B and EV of $2.7B.
BioCryst Pharma's trades at 6.1x EV/Revenue multiple, and 214.4x EV/EBITDA.
Equity research analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioCryst Pharma has a P/E ratio of -48.4x.
See valuation multiples for BioCryst Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 72.0x | XXX | 214.4x | XXX | XXX | XXX |
| EV/EBIT | 62.0x | XXX | -1079.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -48.4x | XXX | -25.3x | XXX | XXX | XXX |
| EV/FCF | 33.9x | XXX | -51.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioCryst Pharma's last 12 month revenue growth is 25%
BioCryst Pharma's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.8M for the same period.
BioCryst Pharma's rule of 40 is -10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioCryst Pharma's rule of X is 70% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioCryst Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 180% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -10% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 70% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioCryst Pharma acquired XXX companies to date.
Last acquisition by BioCryst Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . BioCryst Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioCryst Pharma founded? | BioCryst Pharma was founded in 1991. |
| Where is BioCryst Pharma headquartered? | BioCryst Pharma is headquartered in United States of America. |
| How many employees does BioCryst Pharma have? | As of today, BioCryst Pharma has 580 employees. |
| Who is the CEO of BioCryst Pharma? | BioCryst Pharma's CEO is Mr. Jon P. Stonehouse. |
| Is BioCryst Pharma publicy listed? | Yes, BioCryst Pharma is a public company listed on NAS. |
| What is the stock symbol of BioCryst Pharma? | BioCryst Pharma trades under BCRX ticker. |
| When did BioCryst Pharma go public? | BioCryst Pharma went public in 1994. |
| Who are competitors of BioCryst Pharma? | Similar companies to BioCryst Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioCryst Pharma? | BioCryst Pharma's current market cap is $2.2B |
| What is the current revenue of BioCryst Pharma? | BioCryst Pharma's last 12 months revenue is $518M. |
| What is the current revenue growth of BioCryst Pharma? | BioCryst Pharma revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of BioCryst Pharma? | Current revenue multiple of BioCryst Pharma is 5.3x. |
| Is BioCryst Pharma profitable? | Yes, BioCryst Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioCryst Pharma? | BioCryst Pharma's last 12 months EBITDA is $38.1M. |
| What is BioCryst Pharma's EBITDA margin? | BioCryst Pharma's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of BioCryst Pharma? | Current EBITDA multiple of BioCryst Pharma is 72.0x. |
| What is the current FCF of BioCryst Pharma? | BioCryst Pharma's last 12 months FCF is $81.1M. |
| What is BioCryst Pharma's FCF margin? | BioCryst Pharma's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of BioCryst Pharma? | Current FCF multiple of BioCryst Pharma is 33.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
